Intrapleural Gene Transfer for Pleural Mesothelioma



Status:Completed
Conditions:Lung Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:11/11/2017
Start Date:February 2009
End Date:May 2015

Use our guide to learn which trials are right for you!

A Pilot Study of Repeated Dose Intrapleural Adenoviral-Mediated Interferon-Alpha (SCH 721015, Ad.hIFN-a2b) Gene Transfer for Malignant Pleural Mesothelioma

This research will study how to activate the immune system by using gene transfer. Gene
transfer involves inserting a specially designed gene into cancer cells. A gene is a part of
the genetic code that instructs the cells of our bodies to produce specific compounds
(proteins) important for the makeup or function of the cell. The study hypothesis is that
repeated doses of SCH 721015 given over a three day interval would result in gene transfer.

Ad.hIFN-α (SCH 721015, adenoviral-mediated interferon alpha) is a replication-defective
recombinant adenoviral vector containing the human interferon-alpha (hIFN-alpha) gene. This
Phase I study is designed to evaluate the safety and maximum tolerated dose (MTD) of two
doses of Ad.hIFN-alpha injected into the pleural (intrapleural, IP) and given 4 days apart in
subjects with pleural mesothelioma.

Subjects who meet eligibility will have a pleural catheter placed 2 weeks prior to the first
dose. Subjects are then admitted to the research center on Days 1 and 4 for dosing and
overnight observation. Subjects are then followed-up as outpatients for a total of 6 months.
Radiographic evaluations are repeated on Day 64 and at 6 months. The pleural catheter is
removed once it is not necessary.

Inclusion Criteria:

- evidence of progressive disease after standard first line treatment of mesothelioma;
OR patient has refused standard first line treatment of mesothelioma

- evaluable disease

- No radiotherapy and/or treatment with chemotherapeutic, cytotoxic, or immunologic
agents within 14 days prior to infusion of the IFN-α vector

- Must have a pleural space involved with tumor accessible for pleural catheter
insertion

- FEV1> 1 liter or 40% of predicted value

- Must have an anti-adenoviral neutralizing antibody titer equal to or less than 1:1000.
This will be measured by the Penn Vector Core

Exclusion Criteria:

- Presence of HIV or Hepatitis B infection

- Use of concurrent systemic steroids, immunosuppressives, or any other medications that
can directly or indirectly suppress the immune system

- Presence of any other life-threatening illness, such as unstable angina, severe oxygen
dependence, significant chronic obstructive pulmonary disease (COPD), end stage liver
or renal disease

- Presence of untreated brain metastases

- Prior bone marrow or stem cell transplants
We found this trial at
1
site
3451 Walnut St
Philadelphia, Pennsylvania 19104
1 (215) 898-5000
Univ of Pennsylvania Penn has a long and proud tradition of intellectual rigor and pursuit...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials